In Celexir’s muscle–recovery category, TB-500 is positioned for tendon, ligament, and muscle regeneration—used as an adjunct in orthopedic recovery and athletic rehab where providers want tissue-level support alongside load management, sleep, and inflammation control. Catalog protocols emphasize ready-to-use pens, high purity, and cold-chain handling so dosing is consistent from warehouse to administration.
Mechanistically, TB-500 is a synthetic Thymosin β4 analog that promotes cell migration, angiogenesis, and cytoskeletal organization in healing tissues—functions tied to Tβ4’s actin-binding/sequestration and wound-healing biology documented across basic research. These pathways map to faster granulation, re-epithelialization, and vascular support during repair.
Evidence & diligence: Human, randomized clinical data for TB-500 remain limited; most findings are preclinical. Regulatory bodies also flag caution: not FDA-approved and included on lists of bulk substances that may present safety risks if compounded; WADA prohibits Thymosin-β4 and derivatives (e.g., TB-500) in sport. Frame use, where legal, as investigational, with informed consent and objective tracking (time-to-function, pain/function scores).
Celexir delivery & specs: typical catalog dosing 2–5 mg/week (injury-severity dependent); >98% purity; 2–8 °C storage; CoA provided; injectable pen formulation for clean clinic workflows. For complex injuries, Celexir also offers a TB-500 + BPC-157 co-formulation to combine angiogenesis, collagen support, and NO-pathway signaling.